Completed OBSERVATIONAL NCT01148914

The Role of Cardiac Biomarkers in Prediction of Outcome in Atrial Fibrillation Patients Undergoing Catheter Ablation (IMPACT)

Sponsor: Texas Cardiac Arrhythmia Research Foundation

Updated 7 times since 2017 Last updated: May 31, 2012 Started: Jun 30, 2010 Primary completion: Apr 30, 2012 Completion: Apr 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Atrial Fibrillation, this trial is completed. The trial is conducted by Texas Cardiac Arrhythmia Research Foundation and has accumulated 7 data snapshots since 2010. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: PHASE3 → None

▶ Show 2 earlier versions

Feb 2017 — Apr 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jun 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Texas Cardiac Arrhythmia Research Foundation

Data source: Texas Cardiac Arrhythmia Research Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Austin, United States